Understanding ICH Q11—FDA's Guidance on the Development and Manufacture of Drug Substances - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Understanding ICH Q11—FDA's Guidance on the Development and Manufacture of Drug Substances
The author provides a review of FDA's guidance document, Guidance for Industry: Q11 Development and Manufacture of Drug Substances, and its relation to the International Conference on Harmonization's Q11 document and its application to the industry.


Pharmaceutical Technology
Volume 37, Issue 5, pp. 64-68

Summary

In summary, FDA's guidance for industry, premised on ICH Q11, provides a blueprint for drug-substance manufacturers to follow when preparing a submission as part of the drug- substance application process, regardless whether a traditional or enhanced approach to design and development is pursued. It is imperative that subsidiary ICH and FDA guidance documents be reviewed and understood as these documents provide relevant information required as part of the drug-substance submission process. Fundamental requirements needing to be described, in sufficient detail, in support of the submission process are design and development, manufacturing processes, control strategy, use of starting materials, CQAs, approach to QRM, design space, and approach to continuous improvement. In closing, the CTD format has become the prescribed submission format for regulatory authorities. Ensuring that all of the technical data (i.e., quality, safety, and efficacy) required by the CTD format is organized by specific module will hopefully facilitate an orderly and efficient review of the drug substance application by the appropriate regulatory body.

References

1. FDA, Guidance for Industry: Q11 Development And Manufacture Of Drug Substances (FDA, November 2012).

2. ICH, Q11 Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/biological Entities) (May 2012).

3. ICH, ICH Website homepage, http://www.ich.org/, accessed January 12, 2013.

4. ICH, Q8 (R2) Pharmaceutical Development (ICH, August 2009).

5. FDA, Guidance for Industry: Q7A Good Manufacturing Guidance For Active Pharmaceutical Ingredients (FDA, August 2001).

6. ICH, Q5A (R1) Chemical Synthesis and Elements of Biological Origin (ICH, September 1999).

7. ICH, Q5B Quality Of Biotechnological Products: Analysis Of The Expression Construct In Cells Used For Production of R-DNA Derived Protein Products (ICH, November 1995).

8. ICH, Q5C Quality of Biotechnological Products: Stability Testing Of Biotechnological/Biological Products (ICH, November 1995).

9. ICH, Q5D Derivation and Characterization of Cell Substrates Used for Production Of Biotechnological/Biological Products (ICH, July 1997).

10. ICH, Q5E Compatibility Of Biotechnological/Biological Products Subject To Changes In Their Manufacturing Process (ICH, November 2004).

11. FDA, Draft—Guidance For Industry: Providing Regulatory Submissions In Electronic Format—Certain Human Pharmaceutical Product Applications And Related Submissions Using the eCTD Specifications (FDA, January 2013).

12. FDA, Guidance for industry: M4Q: CTD–Quality (FDA, August 2001).

13. ICH, M4 (R3) Organization Of The Common Technical Document For The Registration Of Pharmaceuticals For Human Use (ICH, January 2004).

14. ICH, M4E (R1) The Common Technical Document For The Registration Of Pharmaceuticals For Human Use: Efficacy (ICH, September 2002).

15. ICH, M4Q (R1) The Common Technical Document For The Registration Of Pharmaceuticals For Human Use: Quality (ICH, September 2002).

16. ICH, M4S (R2) The Common Technical Document For The Registration Of Pharmaceuticals For Human Use: Safety (ICH, December 2002). PT

Bob Mehta is a principal consultant and recruiter at http://www.gmpisoexpert.com/ and provides consulting service in pharma, biotech, medical device, API, and food/dietary supplement industries,

Submitted: Dec. 28, 2012. Accepted: January 24, 2013.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here